These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 38416773)

  • 1. Differential Effects of Type 2 Diabetes Treatment Regimens on Diabetes Distress and Depressive Symptoms in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Gonzalez JS; Bebu I; Krause-Steinrauf H; Hoogendoorn CJ; Crespo-Ramos G; Presley C; Naik AD; Kuo S; Johnson ML; Wexler D; Crandall JP; Bantle AE; Arends V; Cherrington AL;
    Diabetes Care; 2024 Apr; 47(4):610-619. PubMed ID: 38416773
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    ; Nathan DM; Lachin JM; Balasubramanyam A; Burch HB; Buse JB; Butera NM; Cohen RM; Crandall JP; Kahn SE; Krause-Steinrauf H; Larkin ME; Rasouli N; Tiktin M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1063-1074. PubMed ID: 36129996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Effects of Glucose-Lowering Medications on Kidney Outcomes in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Wexler DJ; de Boer IH; Ghosh A; Younes N; Bebu I; Inzucchi SE; McGill JB; Mudaliar S; Schade D; Steffes MW; Tamborlane WV; Tan MH; Ismail-Beigi F;
    JAMA Intern Med; 2023 Jul; 183(7):705-714. PubMed ID: 37213109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Emulating the GRADE trial using real world data: retrospective comparative effectiveness study.
    Deng Y; Polley EC; Wallach JD; Dhruva SS; Herrin J; Quinto K; Gandotra C; Crown W; Noseworthy P; Yao X; Lyon TD; Shah ND; Ross JS; McCoy RG
    BMJ; 2022 Oct; 379():e070717. PubMed ID: 36191949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline Characteristics of Randomized Participants in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Wexler DJ; Krause-Steinrauf H; Crandall JP; Florez HJ; Hox SH; Kuhn A; Sood A; Underkofler C; Aroda VR;
    Diabetes Care; 2019 Nov; 42(11):2098-2107. PubMed ID: 31391203
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Use of Rescue Insulin in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Hollander PA; Krause-Steinrauf H; Butera NM; Kazemi EJ; Ahmann AJ; Fattaleh BN; Johnson ML; Killean T; Lagari VS; Larkin ME; Legowski EA; Rasouli N; Willis HJ; Martin CL;
    Diabetes Care; 2024 Apr; 47(4):638-645. PubMed ID: 37756542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In patients with type 2 diabetes on metformin, the addition of which antihyperglycemic class among a sulfonylurea (glimepiride), a DPP-4 inhibitor (sitagliptin), a GLP-1 agonist (liraglutide), or basal insulin (glargine) is the most effective to achieve and maintain good glycemic control?].
    Lanthier L; Mutchmore A; Plourde MÉ; Cauchon M
    Rev Med Interne; 2023 Jan; 44(1):48-49. PubMed ID: 36443201
    [No Abstract]   [Full Text] [Related]  

  • 8. Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    ; Nathan DM; Lachin JM; Bebu I; Burch HB; Buse JB; Cherrington AL; Fortmann SP; Green JB; Kahn SE; Kirkman MS; Krause-Steinrauf H; Larkin ME; Phillips LS; Pop-Busui R; Steffes M; Tiktin M; Tripputi M; Wexler DJ; Younes N
    N Engl J Med; 2022 Sep; 387(12):1075-1088. PubMed ID: 36129997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
    Garvey WT; Cohen RM; Butera NM; Kazemi EJ; Younes N; Rosin SP; Suratt CE; Ahmann A; Hollander PA; Krakoff J; Martin CL; Seaquist E; Steffes MW; Lachin JM;
    Diabetes Care; 2024 Apr; 47(4):562-570. PubMed ID: 38285957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist liraglutide: A randomized controlled trial in patients with type 2 diabetes.
    Nauck MA; Kahle M; Baranov O; Deacon CF; Holst JJ
    Diabetes Obes Metab; 2017 Feb; 19(2):200-207. PubMed ID: 27709794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rationale and design of the glycemia reduction approaches in diabetes: a comparative effectiveness study (GRADE).
    Nathan DM; Buse JB; Kahn SE; Krause-Steinrauf H; Larkin ME; Staten M; Wexler D; Lachin JM;
    Diabetes Care; 2013 Aug; 36(8):2254-61. PubMed ID: 23690531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative Effects of Randomized Second-line Therapy for Type 2 Diabetes on a Composite Outcome Incorporating Glycemic Control, Body Weight, and Hypoglycemia: An Analysis of the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Kirkman MS; Tripputi M; Krause-Steinrauf H; Bebu I; AbouAssi H; Burch H; Duran-Valdez E; Florez H; Garvey WT; Hsia DS; Salam M; Pop-Busui R;
    Diabetes Care; 2024 Apr; 47(4):594-602. PubMed ID: 38194519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease.
    Yan J; Yao B; Kuang H; Yang X; Huang Q; Hong T; Li Y; Dou J; Yang W; Qin G; Yuan H; Xiao X; Luo S; Shan Z; Deng H; Tan Y; Xu F; Xu W; Zeng L; Kang Z; Weng J
    Hepatology; 2019 Jun; 69(6):2414-2426. PubMed ID: 30341767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal Effects of Glucose-Lowering Medications on β-Cell Responses and Insulin Sensitivity in Type 2 Diabetes: The GRADE Randomized Clinical Trial.
    Rasouli N; Younes N; Ghosh A; Albu J; Cohen RM; DeFronzo RA; Diaz E; Sayyed Kassem L; Luchsinger JA; McGill JB; Sivitz WI; Tamborlane WV; Utzschneider KM; Kahn SE;
    Diabetes Care; 2024 Apr; 47(4):580-588. PubMed ID: 38211595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Insulin Sensitivity and β-Cell Function Over Time on Glycemic Outcomes in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE): Differential Treatment Effects of Dual Therapy.
    Utzschneider KM; Younes N; Butera NM; Balasubramanyam A; Bergenstal RM; Barzilay J; DeSouza C; DeFronzo RA; Elasy T; Krakoff J; Kahn SE; Rasouli N; Valencia WM; Sivitz WI;
    Diabetes Care; 2024 Apr; 47(4):571-579. PubMed ID: 38190619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of Glucose-Lowering Medications on Health-Related Quality of Life in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
    Cherrington AL; Tripputi MT; Younes N; Herman WH; Katona A; Groessl EJ; Craig J; Gonzalez JS; Garg R; Casula S; Kuo S; Florez HJ;
    Diabetes Care; 2024 Apr; 47(4):603-609. PubMed ID: 38190625
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial.
    Russell-Jones D; Vaag A; Schmitz O; Sethi BK; Lalic N; Antic S; Zdravkovic M; Ravn GM; Simó R;
    Diabetologia; 2009 Oct; 52(10):2046-55. PubMed ID: 19688338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In type 2 diabetes, glargine and liraglutide each improved glycemic outcomes at 5 y vs. glimepiride or sitagliptin.
    Brown K; Donato AA
    Ann Intern Med; 2023 Jan; 176(1):JC8. PubMed ID: 36592465
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
    Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
    Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase-4 inhibitor sitagliptin when initiating insulin glargine therapy in patients with type 2 diabetes: The CompoSIT-I Study.
    Roussel R; Duran-García S; Zhang Y; Shah S; Darmiento C; Shankar RR; Golm GT; Lam RLH; O'Neill EA; Gantz I; Kaufman KD; Engel SS
    Diabetes Obes Metab; 2019 Apr; 21(4):781-790. PubMed ID: 30393950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.